^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PTGDR2 (Prostaglandin D2 Receptor 2)

    i
    Other names: PTGDR2, Prostaglandin D2 Receptor 2, CRTH2, CD294, GPR44, DP2, Chemoattractant Receptor Homologous Molecule Expressed On T Helper Type 2 Cells, G-Protein Coupled Receptor 44, DL1R, Chemoattractant Receptor-Homologous Molecule Expressed On TH2 Cells, Chemoattractant Receptor-Homologous Molecule Expressed On Th2 Cells, Putative G-Protein Coupled Receptor 44, G Protein-Coupled Receptor 44, CD294 Antigen
    Associations

    News

    Trials
    19d
    Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development. (PubMed, Nat Commun)
    We also identify a human ILC1 subset as Lin-CD127+CD161-CRTH2-CD117- (CD161- ILC1s) that can be generated from umbilical cord blood CD34+ hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • IL7R (Interleukin 7 Receptor) • KLRB1 (Killer Cell Lectin Like Receptor B1) • PTGDR2 (Prostaglandin D2 Receptor 2)
    2ms
    Expression of Type 2 Innate Lymphoid Cell and IL-9 and Other Related Cytokines in Chronic Lymphocytic Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    In CLL patients, the proportions of ILC2 and IL-9 in peripheral blood and lymph nodes increase, and ILC2 and IL-9 show colocalization in lymph nodes. There is a positive correlation between ILC2 and IL-9 in the peripheral blood of CLL patients, the ability of ILC2 to secrete IL-9 is increased, and ILC2 may affect the occurrence and development of CLL through IL-9.
    Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • GATA3 (GATA binding protein 3) • IL21 (Interleukin 21) • PTGDR2 (Prostaglandin D2 Receptor 2)
    2ms
    Cordyceps sinensis (CS) Alleviates Chronic Obstructive Pulmonary Disease Symptoms (COPD) by Targeting Inflammation, Apoptosis, and Oxidative Stress Through Ingredient-Gene-Disease Interaction. (PubMed, Immun Inflamm Dis)
    CS alleviates COPD symptoms by suppressing inflammation, apoptosis, and oxidative stress, suggesting novel therapeutic strategies.
    Journal • PARP Biomarker
    |
    HMOX1 (Heme Oxygenase 1) • MMP1 (Matrix metallopeptidase 1) • PTGDR (Prostaglandin D2 Receptor 2) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    cordycepin (OVI-123)
    9ms
    Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9. (PubMed, Cancer Immunol Immunother)
    ILC2s affect CD8+ T cells and Treg cells through IL-9, weakening the anti-tumor effects of CD8+ T cells and enhancing the immunosuppressive effects of Treg cells, thereby contributing to CLL pathogenesis.
    Journal
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B) • GATA3 (GATA binding protein 3) • PTGDR2 (Prostaglandin D2 Receptor 2)
    1year
    PGD2/PTGDR2 Signaling Affects the Stemness of Gastric Cancer Stem Cells by Regulating Autophagy. (PubMed, Comb Chem High Throughput Screen)
    In summary, this study indicated that PGD2/PTGDR2 signaling affects stemness and autophagy in GCSCs. The results suggest that PGD2/PTGDR2 signaling may affect the stemness of GCSCs by regulating autophagy.
    Journal
    |
    POU5F1 (POU Class 5 Homeobox 1) • PTGDR (Prostaglandin D2 Receptor 2) • PTGDR2 (Prostaglandin D2 Receptor 2)
    1year
    PGD2/PTGDR2 signaling pathway affects the self-renewal capacity of gastric cancer stem cells by regulating ATG4B ubiquitination. (PubMed, Front Oncol)
    Moreover, PTGDR2 knockdown blocked the activation of autophagy by PGD2 and the level of ATG4B ubiquitination in GCSCs. In summary, it was elucidated that the PGD2/PTGDR2 signaling cascade affects GCSCs stemness by regulating autophagy, suggesting that the PGD2/PTGDR2 signaling pathway could serve as a novel target for cancer therapy.
    Journal
    |
    ATG4B (Autophagy Related 4B Cysteine Peptidase) • PTGDR (Prostaglandin D2 Receptor 2) • PTGDR2 (Prostaglandin D2 Receptor 2)
    over1year
    Single cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis disease group. (PubMed, J Allergy Clin Immunol)
    These data position polyclonal small- and large-plaque dermatitis lesions as a separate disease entity, that characteristically harbors a so far undescribed ILC population. We thus propose the new term "polyclonal parapsoriasis en plaque" to this kind of lesions, as they can be clearly differentiated from early and advanced-stage MF, psoriasis and AD on several cellular and molecular levels.
    Journal
    |
    CD7 (CD7 Molecule) • IL13 (Interleukin 13) • IL3 (Interleukin 3) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    CD7 expression
    over1year
    Circulating subpopulations of non-cytotoxic ILCs in diffuse large B-cell lymphoma. (PubMed, Ann Hematol)
    Our results suggest that circulating ILCs are activated and differentiated and/or differentially recruited to the lymph nodes or tumor microenvironment where they may be involved in antitumor defense. However, our observations require confirmation in functional studies.
    Journal
    |
    IL7R (Interleukin 7 Receptor) • PTGDR2 (Prostaglandin D2 Receptor 2)
    almost2years
    Advances in PGD2/PTGDR2 signaling pathway in tumors: A review. (PubMed, Biomol Biomed)
    Additionally, reduced PGD2 expression has been associated with poor prognosis in patients with gastric, breast, lung, and pancreatic cancers, validating the preclinical findings and their clinical relevance. This review focuses on the current understanding of PGD2/PTGDR2 expression patterns and biological activity in cancer, proposing questions to guide the assessment of PGD2 and its receptors as potential targets for effective cancer therapies.
    Review • Journal
    |
    PTGDR (Prostaglandin D2 Receptor 2) • PTGDR2 (Prostaglandin D2 Receptor 2)
    2years
    Impact of Smoking and Its Cessation on Systemic and Airway Immune Activation (clinicaltrials.gov)
    P=N/A, N=53, Completed, Boston Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    CD8 (cluster of differentiation 8) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD28 (CD28 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR2 (C-C Motif Chemokine Receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8) • ITGAX (Integrin Subunit Alpha X) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    CD38 expression • IL2RA expression
    over2years
    Cellular and molecular profiling of early-stage mycosis fungoides in comparison to parapsoriasis and atopic dermatitis reveals disease-specific markers (ISDS 2023)
    PP, by contrast, characteristically showed elevated expression of coagulation and complement-related genes including F2R, F3 and C7 in fibroblasts, and expansion of a unique NPY+ innate lymphoid cell population that was not found in other disease groups. These data position classic small-patch PP as a separate entity characterized by expansion of specific ILC subsets, distinct from AD and early MF.
    IO biomarker
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD27 (CD27 Molecule) • LGALS3 (Galectin 3) • CD7 (CD7 Molecule) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • IL13 (Interleukin 13) • IL3 (Interleukin 3) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    NTRK expression
    over2years
    Single-Cell Transcriptomic Profiling of T Cells from Blinatumomab-Treated Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Circulating CD8 T Cell Subsets Associated with Treatment Response (ASH 2023)
    The dots represent the observed logFC, the horizontal line the bootstrapped 95%Confidence Intervals; PTGDR2= prostaglandin D2 receptor 2; ns= not significant B) Differentially expressed genes in Non Responders vs Responders CD8pos naïve T cells. FDR=False Discovery Rate; CCL5= Chemokine (C-C motif) ligand 5; PRDM1= PR/SET Domain 1; SGK1= serum/glucocorticoid regulated kinase 1.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL7R (Interleukin 7 Receptor) • CCR7 (Chemokine (C-C motif) receptor 7) • PRDM1 (PR/SET Domain 1) • CCL3 (C-C Motif Chemokine Ligand 3) • GZMK (Granzyme K) • SGK1 (Serum/Glucocorticoid Regulated Kinase 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • IFNGR1 (Interferon Gamma Receptor 1) • PTGDR (Prostaglandin D2 Receptor 2) • PTGDR2 (Prostaglandin D2 Receptor 2)
    |
    Blincyto (blinatumomab)